Eagle Pharmaceuticals (EGRX) Competitors $2.30 0.00 (0.00%) As of 12:53 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EGRX vs. SAVA, VXRT, CRDL, KRRO, VIRI, ADAG, ORMP, OPTN, HLVX, and CCCCShould you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include Cassava Sciences (SAVA), Vaxart (VXRT), Cardiol Therapeutics (CRDL), Korro Bio (KRRO), Virios Therapeutics (VIRI), Adagene (ADAG), Oramed Pharmaceuticals (ORMP), OptiNose (OPTN), HilleVax (HLVX), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry. Eagle Pharmaceuticals vs. Its Competitors Cassava Sciences Vaxart Cardiol Therapeutics Korro Bio Virios Therapeutics Adagene Oramed Pharmaceuticals OptiNose HilleVax C4 Therapeutics Eagle Pharmaceuticals (NASDAQ:EGRX) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and community ranking. Does the MarketBeat Community prefer EGRX or SAVA? Eagle Pharmaceuticals received 314 more outperform votes than Cassava Sciences when rated by MarketBeat users. Likewise, 65.50% of users gave Eagle Pharmaceuticals an outperform vote while only 64.47% of users gave Cassava Sciences an outperform vote. CompanyUnderperformOutperformEagle PharmaceuticalsOutperform Votes41265.50% Underperform Votes21734.50% Cassava SciencesOutperform Votes9864.47% Underperform Votes5435.53% Do analysts prefer EGRX or SAVA? Cassava Sciences has a consensus target price of $54.50, indicating a potential upside of 2,458.69%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is EGRX or SAVA more profitable? Eagle Pharmaceuticals' return on equity of 0.00% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Eagle PharmaceuticalsN/A N/A N/A Cassava Sciences N/A -88.05%-64.98% Do insiders and institutionals hold more shares of EGRX or SAVA? 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 2.4% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to EGRX or SAVA? In the previous week, Cassava Sciences had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 1 mentions for Cassava Sciences and 0 mentions for Eagle Pharmaceuticals. Cassava Sciences' average media sentiment score of 1.61 beat Eagle Pharmaceuticals' score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Overall Sentiment Eagle Pharmaceuticals Neutral Cassava Sciences Very Positive Which has higher valuation & earnings, EGRX or SAVA? Eagle Pharmaceuticals has higher revenue and earnings than Cassava Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEagle Pharmaceuticals$257.55M0.12$35.64MN/AN/ACassava SciencesN/AN/A-$97.22M-$1.50-1.42 Which has more risk and volatility, EGRX or SAVA? Eagle Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -1.99, indicating that its stock price is 299% less volatile than the S&P 500. SummaryEagle Pharmaceuticals beats Cassava Sciences on 9 of the 14 factors compared between the two stocks. Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EGRX vs. The Competition Export to ExcelMetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.87M$6.94B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E RatioN/A8.8427.2520.00Price / Sales0.12265.40413.35158.30Price / Cash0.4065.8538.2534.64Price / BookN/A6.617.124.70Net Income$35.64M$144.20M$3.24B$248.14M7 Day Performance4.55%4.00%2.71%2.48%1 Month Performance15.58%11.33%8.93%6.15%1 Year Performance-37.33%3.91%31.30%13.59% Eagle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EGRXEagle PharmaceuticalsN/A$2.30flatN/A-37.5%$29.87M$257.55M0.00100Gap DownSAVACassava Sciences4.2777 of 5 stars$2.13+6.0%$54.50+2,458.7%-88.9%$102.90MN/A-1.5430Positive NewsVXRTVaxart2.1121 of 5 stars$0.45+3.9%$3.00+566.7%-34.5%$102.70M$47.40M-1.10120Gap DownCRDLCardiol Therapeutics2.3466 of 5 stars$1.24-0.8%$8.67+598.9%-51.0%$102.44MN/A-3.1820Gap UpKRROKorro Bio3.5686 of 5 stars$10.80-5.4%$102.43+848.4%-64.8%$101.42M$4.82M-1.1470Positive NewsAnalyst RevisionHigh Trading VolumeVIRIVirios TherapeuticsN/A$5.18-2.1%$3.00-42.1%+2,104.8%$99.76MN/A-19.195ADAGAdagene2.7221 of 5 stars$2.09+7.5%$8.00+283.7%-32.0%$98.22M$103.20K0.00260Positive NewsGap DownORMPOramed Pharmaceuticals1.8668 of 5 stars$2.38+1.7%N/A+7.7%$97.22M$2M21.6410OPTNOptiNose1.8038 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190HLVXHilleVax3.2541 of 5 stars$1.93+3.2%$3.00+55.4%-86.7%$96.77MN/A-0.6220Positive NewsCCCCC4 Therapeutics2.2125 of 5 stars$1.33+6.4%$12.00+802.3%-68.7%$94.44M$39.78M-0.78150Positive News Related Companies and Tools Related Companies SAVA Alternatives VXRT Alternatives CRDL Alternatives KRRO Alternatives VIRI Alternatives ADAG Alternatives ORMP Alternatives OPTN Alternatives HLVX Alternatives CCCC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EGRX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
